EIF3B is associated with poor outcomes in gastric cancer patients and promotes cancer progression via the PI3K/AKT/mTOR signaling pathway

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• He W, Tu J, Huo Z, et al. Surgical interventions for gastric cancer: a review of systematic reviews. Int J Clin Exp Med. 2015;8(8):13657–13669.26550311
   PubMed Web of Science ®Google Scholar
• Aoyama T, Yoshikawa T. Adjuvant therapy for locally advanced gastric cancer. Surg Today. 2017;47(11):1295–1302. doi:10.1007/s00595-017-1493-y28251375
   PubMed Web of Science ®Google Scholar
• Sun KK, Shen XJ, Yang D, et al. MicroRNA-31 triggers G2/M cell cycle arrest, enhances the chemosensitivity and inhibits migration and invasion of human gastric cancer cells by downregulating the expression of zeste homolog 2 (ZH2). Arch Biochem Biophys. 2019;663:269–275. doi:10.1016/j.abb.2019.01.02330677405
   PubMed Web of Science ®Google Scholar
• Duo-Ji MM, Ci-Ren BS, Long ZW, Zhang XH, Luo DL. Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis. Oncotarget. 2017;8(23):37896–37911. doi:10.18632/oncotarget.1466428099947
   PubMedGoogle Scholar
• Kanat O, O’Neil BH. Metastatic gastric cancer treatment: a little slow but worthy progress. Med Oncol. 2013;30(1):464. doi:10.1007/s12032-013-0464-423335104
   PubMed Web of Science ®Google Scholar
• Spriggs KA, Bushell M, Willis AE. Translational regulation of gene expression during conditions of cell stress. Mol Cell. 2010;40(2):228–237. doi:10.1016/j.molcel.2010.09.02820965418
   PubMed Web of Science ®Google Scholar
• Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009;136(4):731–745. doi:10.1016/j.cell.2009.01.04219239892
   PubMed Web of Science ®Google Scholar
• Yu X, Zheng B, Chai R. Lentivirus-mediated knockdown of eukaryotic translation initiation factor 3 subunit D inhibits proliferation of HCT116 colon cancer cells. Biosci Rep. 2014;34(6):e00161. doi:10.1042/BSR2014007825370813
   PubMedGoogle Scholar
• Jackson RJ, Hellen CU, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol. 2010;11(2):113–127. doi:10.1038/nrm283820094052
   PubMed Web of Science ®Google Scholar
• des Georges A, Dhote V, Kuhn L, et al. Structure of mammalian eIF3 in the context of the 43S preinitiation complex. Nature. 2015;525(7570):491–495. doi:10.1038/525S9a26344199
   PubMed Web of Science ®Google Scholar
• Feng X, Li J, Liu P. The biological roles of translation initiation factor 3b. Int J Biol Sci. 2018;14(12):1630–1635. doi:10.7150/ijbs.2462630416377
   PubMed Web of Science ®Google Scholar
• Liu Y, Neumann P, Kuhle B, et al. Translation initiation factor eIF3b contains a nine-bladed beta-propeller and interacts with the 40S ribosomal subunit. Structure. 2014;22(6):923–930. doi:10.1016/j.str.2014.03.01024768115
   PubMed Web of Science ®Google Scholar
• Zhang L, Pan X, Hershey JW. Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells. J Biol Chem. 2007;282(8):5790–5800. doi:10.1074/jbc.M60628420017170115
   PubMed Web of Science ®Google Scholar
• Zang Y, Zhang X, Yan L, et al. Eukaryotic translation initiation factor 3b is both a promising prognostic biomarker and a potential therapeutic target for patients with clear cell renal cell carcinoma. J Cancer. 2017;8(15):3049–3061. doi:10.7150/jca.1959428928896
   PubMed Web of Science ®Google Scholar
• Xu F, Xu CZ, Gu J, et al. Eukaryotic translation initiation factor 3B accelerates the progression of esophageal squamous cell carcinoma by activating beta-catenin signaling pathway. Oncotarget. 2016;7(28):43401–43411.27270324
   PubMedGoogle Scholar
• Wang H, Ru Y, Sanchez-Carbayo M, Wang X, Kieft JS, Theodorescu D. Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization. Clin Cancer Res. 2013;19(11):2850–2860. doi:10.1158/1078-0432.CCR-12-308423575475
   PubMed Web of Science ®Google Scholar
• In H, Solsky I, Palis B, Langdon-Embry M, Ajani J, Sano T. Validation of the 8th Edition of the AJCC TNM staging system for gastric cancer using the national cancer database. Ann Surg Oncol. 2017;24(12):3683–3691. doi:10.1245/s10434-017-6078-x28895113
   PubMed Web of Science ®Google Scholar
• Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108(3):479–485. doi:10.1038/bjc.2012.49423299535
   PubMed Web of Science ®Google Scholar
• Yin Y, Long J, Sun Y, et al. The function and clinical significance of eIF3 in cancer. Gene. 2018;673:130–133. doi:10.1016/j.gene.2018.06.03429908282
   PubMed Web of Science ®Google Scholar
• Tian Y, Zhao K, Yuan L, et al. EIF3B correlates with advanced disease stages and poor prognosis, and it promotes proliferation and inhibits apoptosis in non-small cell lung cancer. Cancer Biomark. 2018;23(2):291–300. doi:10.3233/CBM-18162830198870
   PubMed Web of Science ®Google Scholar
• Golob-Schwarzl N, Krassnig S, Toeglhofer AM, et al. New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors. Eur J Cancer. 2017;83:56–70. doi:10.1016/j.ejca.2017.06.00328715695
   PubMed Web of Science ®Google Scholar
• Wagner S, Herrmannova A, Sikrova D, Valasek LS. Human eIF3b and eIF3a serve as the nucleation core for the assembly of eIF3 into two interconnected modules: the yeast-like core and the octamer. Nucleic Acids Res. 2016;44(22):10772–10788. doi:10.1093/nar/gkw97227924037
   PubMed Web of Science ®Google Scholar
• Li B, Huang C. Regulation of EMT by STAT3 in gastrointestinal cancer (Review). Int J Oncol. 2017;50(3):753–767. doi:10.3892/ijo.2016.376228098855
   PubMed Web of Science ®Google Scholar
• Kang FB, Wang L, Jia HC, et al. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int. 2015;15:45. doi:10.1186/s12935-015-0195-z25908926
   PubMed Web of Science ®Google Scholar
• Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960–976. doi:10.1016/j.cell.2017.02.00428283069
   PubMed Web of Science ®Google Scholar
• Xu K, Liu P, Wei W. mTOR signaling in tumorigenesis. Biochim Biophys Acta. 2014;1846(2):638–654.25450580
   PubMed Web of Science ®Google Scholar
• Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer. 2010;10(4):254–266. doi:10.1038/nrc282420332778
   PubMed Web of Science ®Google Scholar
• Yecies JL, Manning BD. mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med (Berl). 2011;89(3):221–228. doi:10.1007/s00109-011-0726-621301797
   PubMed Web of Science ®Google Scholar
• Demosthenous C, Han JJ, Stenson MJ, et al. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. Oncotarget. 2015;6(11):9488–9501. doi:10.18632/oncotarget.337825839159
   PubMedGoogle Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21–35. doi:10.1038/nrm302521157483
   PubMed Web of Science ®Google Scholar